patent/BR-PI0618705-B8

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0618705-B8

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77398fa807de9314d33d70e5f30c15c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c244a100da35c81a9fe54c410efdffc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2403aad8bbbf284fed86d63332054c16
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24
filingDate	2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95e9f134e75d9c89a3285561a2c0c8d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bbcf9e1b5b1359f8830776205dcbb43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3a76c0ab6404e13745f80842aeb3180 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b03caeca0d91cca603796b462ea9a62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ec0ea90e4f2879991ea4613e044c4b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6149ce7be5189201d81bc0755acc4022
publicationDate	2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	BR-PI0618705-B8
titleOfInvention	humanized antagonist antibodies directed against calcitonin gene-related peptide, pharmaceutical composition and use thereof
abstract	antagonist antibodies directed against calcitonin gene-related peptide, pharmaceutical composition and use thereof. The present invention relates to methods for preventing or treating disorders associated with cgrp, such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and fevers, for example. administration of an antagonist anti-cgrp antibody. the g1 antagonist antibody and g1 derived antibodies directed to cgrp are also described.
priorityDate	2005-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16132372 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP10286 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP30880 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP30881 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448517942 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP31888

Total number of triples: 52.